Tag #Weight Loss

Showing 25 to 36 of 116 results

zeit.de

🌐 85% Global Worthiness

Aug 8, 16:18

Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial

Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...

Eli Lilly's Orforglipron Shows Promise in Weight Loss Trial

Eli Lilly's Phase 3 trial of Orforglipron, an oral GLP-1 receptor agonist for weight loss, showed a 12.4% average weight loss in obese adults after 72 weeks, prompting plans for FDA approval by year's end; however, experts voice concerns about the yo-yo effect and lack of comparison to effective non...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of Eli Lilly's successful Phase 3 trial for Orforglipron, and what are its immediate implications for weight management?

Eli Lilly's Orforglipron, a new oral GLP-1 receptor agonist, showed a 12.4% average weight loss in obese adults over 72 weeks in a Phase 3 trial, compared to 0.9% in the placebo group. The company plans to seek FDA approval by year's end, offering an alternative to injectable treatments. Common side effects included nausea, constipation, diarrhea, and vomiting.

us.cnn.com

🌐 85% Global Worthiness

Aug 7, 16:17

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Eli Lilly's orforglipron Phase 3 trial results on obesity treatment?

In a Phase 3 trial, Eli Lilly's orforglipron, a once-daily oral GLP-1 pill, facilitated a 12.4% average weight reduction in obese adults over 72 weeks. This involved 3,127 participants with at least one weight-related health issue, excluding diabetes. The highest dose resulted in 59.6% achieving 10% weight loss and 39.6% achieving 15% weight loss.

bbc.com

🌐 65% Global Worthiness

Jul 26, 19:12

70.3-Mile Ironman Triathlon Completed by Man Who Could Not Swim a Length

Owen Peddle, a 23.5-stone man previously unable to swim a length, completed a 70.3-mile Ironman triathlon in Swansea on July 6th, 2024, after nine months of rigorous training inspired by friends and documented on social media, losing 25kg and improving his mental health.

70.3-Mile Ironman Triathlon Completed by Man Who Could Not Swim a Length

Owen Peddle, a 23.5-stone man previously unable to swim a length, completed a 70.3-mile Ironman triathlon in Swansea on July 6th, 2024, after nine months of rigorous training inspired by friends and documented on social media, losing 25kg and improving his mental health.

Progress

28% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did social media and the support of friends influence Peddle's training and success?

Inspired by friends' Ironman completion, Peddle set a challenging goal to overcome physical limitations and improve mental well-being. He documented his training on social media, building a supportive online community. His success highlights the role of social support and self-discipline in achieving ambitious fitness goals.

foxnews.com

🌐 75% Global Worthiness

Jul 21, 01:11

Meal Sequencing: Eating Order Impacts Blood Sugar, Weight

The order of food consumption may significantly affect blood sugar levels and weight; eating fiber-rich vegetables before protein, fats, and carbohydrates can help prevent blood sugar spikes, increase fullness, and aid in weight loss, according to nutrition experts.

Meal Sequencing: Eating Order Impacts Blood Sugar, Weight

The order of food consumption may significantly affect blood sugar levels and weight; eating fiber-rich vegetables before protein, fats, and carbohydrates can help prevent blood sugar spikes, increase fullness, and aid in weight loss, according to nutrition experts.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does prioritizing the order of food consumption impact blood sugar levels and weight management?

Meal sequencing, a method of eating fiber-rich vegetables before protein, fats, and carbohydrates, may help prevent blood sugar spikes and promote weight loss. Studies show it improves glycemic control and blood sugar levels, particularly benefiting those with insulin resistance or diabetes. However, individual responses vary, and personalized advice from a medical expert is recommended for diabetics.

bbc.com

🌐 85% Global Worthiness

Jul 13, 10:10

Preventing Type 2 Diabetes: Reversing Prediabetes Through Lifestyle Changes

Prediabetes, a precursor to type 2 diabetes, can often be reversed by losing 10% of body weight, adopting a healthy diet (reducing sugary drinks, red and processed meats, and refined carbohydrates while increasing fiber intake), and increasing physical activity; these changes can prevent or delay ty...

Preventing Type 2 Diabetes: Reversing Prediabetes Through Lifestyle Changes

Prediabetes, a precursor to type 2 diabetes, can often be reversed by losing 10% of body weight, adopting a healthy diet (reducing sugary drinks, red and processed meats, and refined carbohydrates while increasing fiber intake), and increasing physical activity; these changes can prevent or delay ty...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do factors such as weight, diet, and genetics contribute to the development of prediabetes?

The risk of prediabetes is influenced by factors like genetics, age, diet, and weight. Excess weight, especially around the abdomen, makes it harder for insulin to control glucose, increasing prediabetes risk. Lifestyle and dietary habits contributing to excess body fat significantly raise the risk.

news.sky.com

🌐 85% Global Worthiness

Jun 26, 10:15

UK Weight-Loss Injections Linked to Pancreatitis Cases

Over a million people in the UK have used weight loss and diabetes jabs, with the Medicines and Healthcare products Regulatory Agency (MHRA) reporting 294 cases of pancreatitis (inflammation of the pancreas) linked to these drugs, including five deaths. A new study will investigate genetic links.

UK Weight-Loss Injections Linked to Pancreatitis Cases

Over a million people in the UK have used weight loss and diabetes jabs, with the Medicines and Healthcare products Regulatory Agency (MHRA) reporting 294 cases of pancreatitis (inflammation of the pancreas) linked to these drugs, including five deaths. A new study will investigate genetic links.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the reported pancreatitis cases linked to weight-loss injections in the UK?

Over one million Britons have used weight-loss and diabetes injections linked to 181 pancreatitis cases and five deaths. The Medicines and Healthcare products Regulatory Agency (MHRA) notes that while there's no direct causal link, a new study will investigate genetic predispositions to this side effect. This highlights the importance of personalized medicine.

abcnews.go.com

🌐 85% Global Worthiness

Aug 7, 16:18

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings from Eli Lilly's Phase 3 trial on the efficacy and safety of orforglipron in weight loss and cardiovascular health?

Eli Lilly announced that its new oral GLP-1 pill, orforglipron, resulted in an average weight loss of 27.3 pounds over 72 weeks in a Phase 3 trial involving over 3,100 overweight or obese adults. The highest dose (36mg) led to approximately 12% body weight reduction. This offers a potential non-injectable alternative to existing treatments.

foxnews.com

🌐 85% Global Worthiness

Aug 1, 22:18

GLP-1 Drugs Show Promise in Treating Rheumatoid Arthritis

GLP-1 medications, used for diabetes and weight loss, show promise in treating rheumatoid arthritis (RA) by potentially reducing inflammation; some patients saw relief and stopped using their RA medications, although more research is needed.

GLP-1 Drugs Show Promise in Treating Rheumatoid Arthritis

GLP-1 medications, used for diabetes and weight loss, show promise in treating rheumatoid arthritis (RA) by potentially reducing inflammation; some patients saw relief and stopped using their RA medications, although more research is needed.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the observed anti-inflammatory effects of GLP-1s potentially impact the treatment and management of rheumatoid arthritis?

The positive effects of GLP-1s extend beyond weight management; they are being investigated for their anti-inflammatory properties. A connection exists between obesity and RA, and GLP-1 medications may mitigate RA by impacting the body's inflammatory response. This is evidenced by patient reports of symptom relief and cessation of other RA medications.

abcnews.go.com

🌐 75% Global Worthiness

Jul 24, 04:12

Weight Regain Follows GLP-1 Medication Discontinuation

A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.

Weight Regain Follows GLP-1 Medication Discontinuation

A study in BMC Medicine reveals that patients stopping GLP-1 weight-loss drugs like Wegovy and Ozempic regain weight within two months, highlighting the chronic nature of obesity and need for ongoing management, despite continued healthy habits.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate effects of stopping GLP-1 weight-loss medications, and what does this imply about the long-term management of obesity?

A new study shows that people who discontinue GLP-1 medications like Wegovy and Ozempic for weight loss regain a significant portion of the lost weight within two months. The weight regain often continues for several months before stabilizing. This is consistent with other chronic disease treatments where the medication's effects cease upon discontinuation.

bbc.com

🌐 30% Global Worthiness

Jul 20, 13:11

Suffolk Man's 8st Weight Loss Through Football Improves Family Life

Alex Hammond, 45, from Ipswich, lost 8st 7lb (55kg) after joining MAN v FAT Football in May 2024, improving his health and relationship with his children and allowing him to be a better role model.

Suffolk Man's 8st Weight Loss Through Football Improves Family Life

Alex Hammond, 45, from Ipswich, lost 8st 7lb (55kg) after joining MAN v FAT Football in May 2024, improving his health and relationship with his children and allowing him to be a better role model.

Progress

12% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate impact did participating in MAN v FAT Football have on Alex Hammond's life and his relationship with his children?

Alex Hammond, a 45-year-old man from Ipswich, lost 8st 7lb (55kg) by participating in MAN v FAT Football. This weight loss allowed him to become more active with his children and coaching youth football teams. He previously weighed 21st 6lb (137kg) and struggled to maintain weight loss before joining the league.",

theglobeandmail.com

🌐 85% Global Worthiness

Jul 4, 01:13

Healthy Diet Improves Cardiometabolic Health Regardless of Weight Loss

A study of 761 obese participants following three different diets found that even those who didn't lose weight experienced significant improvements in cardiometabolic health markers, emphasizing the importance of diet quality regardless of weight change.

Healthy Diet Improves Cardiometabolic Health Regardless of Weight Loss

A study of 761 obese participants following three different diets found that even those who didn't lose weight experienced significant improvements in cardiometabolic health markers, emphasizing the importance of diet quality regardless of weight change.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors might contribute to weight-loss resistance, and how does the study shed light on these factors?

The study analyzed data from three long-term weight loss trials in Israel, involving 761 obese participants following low-carbohydrate, Mediterranean, or green-Mediterranean diets. While some participants achieved clinically significant weight loss (36%), others lost little to no weight (28%) but still saw improvements in key cardiometabolic risk factors. This highlights the independent effect of diet quality on health outcomes.

cincodias.elpais.com

🌐 85% Global Worthiness

Jun 21, 04:14

Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk

Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...

Wegovy's 7.2mg Dose Shows 20.7% Weight Loss in Obese Individuals: Novo Nordisk

Novo Nordisk's STEP UP trial, presented at the ADA 2024 Scientific Sessions, demonstrated that a 7.2mg dose of semaglutide (Wegovy) led to a 20.7% average weight loss in obese individuals without diabetes after 72 weeks, with a third achieving at least 25% weight reduction compared to placebo; the c...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key safety considerations and adverse effects observed in the STEP UP trial related to the 7.2mg semaglutide dose?

Novo Nordisk's findings demonstrate a substantial increase in weight loss compared to lower semaglutide dosages, supporting the drug's efficacy in managing obesity. Even accounting for adherence, participants using 7.2mg semaglutide lost an average of 18.7% of their weight, significantly exceeding placebo results. This reinforces semaglutide's benefits beyond previous indications.

Showing 25 to 36 of 116 results